2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1775 Fixed duration subcutaneous mosunetuzumab induces a high rate of complete and durable responses in patients with previously untreated extranodal marginal zone lymphoma (EMZL)- a phase II study

Izidore S. Lossos, M.D., Kristen Lucas2, Isildinha Reis, PhD3, Michele D. Stanchina, DO,MS4, Alvaro Alencar, MD5, Asaad Trabolsi, MD6, Craig Moskowitz, MD7, Georgios N Pongas8, Daniel Sussman9, Jennifer Chapman, MD10, Russ Kuker, MD11, Juan Pablo Alderuccio, MD12
1 University of Miami, Miami, United States
2 University of Miami, Miami, United States
3 University of Miami, Miami, United States
4 University of Miami, Miami, United States
5 University of Miami, Miami, United States
6 University of Miami, Miami, United States
7 University of Miami, Miami, United States
8 University of Miami, Miami, United States
9 University of Miami, Miami, United States
10 University of Miami, Miami, United States
11 University of Miami, Miami, United States
12 University of Miami, Miami, United States

Introduction: Marginal zone lymphoma (MZL) is a heterogeneous disease representing 7% of non-Hodgkin lymphomas (NHL). The most common subtype is EMZL comprising 61% of all MZL. There is no universally acceptable therapeutic approach to newly diagnosed EMZL patients with only a single randomized trial (IELSG-19) reported. Early complete response (CR) after systemic therapy was recently validated as the best surrogate marker for prolonged progression free survival (PFS) in EMZL patients (PMID: 37801707). Novel and less toxic therapies capable of achieving durable CR are needed. We initiated a phase 2 clinical trial to examine the safety and efficacy of fixed duration (8 cycles) subcutaneous step-up mosunetuzumab (Mosun), a bispecific CD20xCD3 antibody, in inducing CR and improving survival in EMZL patients needing treatment. We report on planned interim analysis.

Methods: This is an open label investigator-initiated study evaluating safety and efficacy of Mosun in newly diagnosed EMZL patients (NCT06569680) that did not receive previous systemic treatment. Adult patients needing treatment based on symptoms, endangered extranodal organ function and other predefined criteria for EMZL were eligible. Patients were staged by routine lymphoma and extranodal organ directed tests, PET-CT and CT or MRI imaging and bone marrow biopsy (BMB). Outpatient treatment is given every 3 weeks with s.c. step-up Mosun (Cycle (C)1: D1- 5mg; D8 and D15- 45mg; C2-8: D1- 45mg). The primary study endpoint is CR after 8 cycles based on Lugano 2014 criteria using PET-CT (if FDG avid) or CT/MRI (for non-avid disease) and repeated BMB if initially involved. Premedication with dexamethasone 20 mg on C1D1, 8 and 15 was required. The study implements a Simon’s minimax two-stage phase 2 clinical trial design with planned interim and final analyses with 13 and 35 evaluable patients, respectively. The null hypothesis was the true CR rate (P) is ≤60% (P0), versus the alternative hypothesis that the true CR rate (P) is ≥80% (P1).

Results: 22 patients were enrolled from December 2024 to July 1, 2026. Median age was 64.5 years (range 33-83) with 12 (54.5%) females. Most patients were Hispanic and non-Hispanic White (45.4%; n= 10, each) followed by Hispanic and non-Hispanic black (4.5%; n=1, each). Twelve distinct extranodal organs were involved with multiple mucosal sites involved in 13 (59.1%) patients. Bone marrow involvement was present in 6 (27.3%), bulky tumor (>6cm) in 4 (18.2%) and 17 (77.3%) patients presented with stage IV. Monoclonal serum paraprotein was detected in 10 (45.5%) patients. Revised MALT-IPI was 0 (n=1), 1 (n=3), 2 (n=4), 3 (n=8) and 4 (n=6). Three patients received prior antibiotics for H. pylori and 2 additional received localized radiation. These 5 patients relapsed with H pylori negative stage IV EMZL.

As of July 15, 2026, 20 patients were evaluable for response with best ORR of 100% with CR in 90% (n=18), PR in 10% (n=2). Most patients (75%; n=15) achieved CR after 4 cycles. The study met the prespecified interim analysis proceeding with phase 2 of Simon’s design. With a median follow-up of 15.2 months (range 7.6-17.5), the PFS and OS were 100%. Updated results will be presented at the meeting.

All 22 patients experienced expected distinctive adverse events (AE; n=192), most commonly grade 1-2; 134 were considered Mosun-related and 58 unrelated. A total of 27 cytokine release syndrome (CRS) events (26-grade 1; 1-grade 2) were observed in 17 (77.2%) patients. All fully recovered either spontaneously or with steroids, but without tocilizumab. 25 CRS events occurred during C1 (mostly after C1D1 dose) and 2 during C2. The single grade 2 CRS occurred on C1D17. No ICANS were observed. Other common grade 1-2 AEs were skin injection site reactions (59.1%), fatigue (45.5%), decrease in neutrophil counts (40.9%), liver enzyme abnormalities (31.8%), infections (22.7%, mostly viral upper respiratory) and diarrhea (22.7%). Three grade 3 and two grade 4 AEs were observed in 3 patients (recurrent neutropenia treated with G-CSF, rash and tumor flare in ocular adnexa EMZL, each in 1 patient). Mosun treatment was not discontinued in any patient.

Conclusion: Mosun treatment is well tolerated and demonstrates high rate of CR in newly diagnosed EMZL patients. With longer follow-up to confirm response durability, these findings may suggest that Mosun may become a preferable therapeutic option in patients with EMZL needing treatment.

Izidore S. Lossos, M.D.: Genentech - Research Funding; Genmab - Research Funding; ADC Therapeutics - Research Funding; Adaptive Biotechnology - Consultancy (Includes expert testimony)